{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093976","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.468683+00:00","generated_at":"2026-05-31T11:06:38.444875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M","bullets":["Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.","Cash and equivalents $251.6M; expects 2024 operating cash burn below $200M.","Four clinical trials ongoing across seven indications; initial data expected in 2024 for SC291, SC262, and UP421.","R&D expenses decreased to $60.9M (Q2 2024) from $73.0M (Q2 2023) due to strategic repositioning.","Non-GAAP operating cash burn for H1 2024 was $104.6M vs $136.5M in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093976","json":"https://secwatch.observer/filing/0000950170-24-093976.json","markdown":"https://secwatch.observer/filing/0000950170-24-093976.md","text":"https://secwatch.observer/filing/0000950170-24-093976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/0000950170-24-093976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024093976/sana-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:06:38.444875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}